GC
DYN icon

Guggenheim Capital’s Dyne Therapeutics DYN Stock Holding History

Guggenheim Capital’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$222K Buy
12,236
+1,165
+11% +$20.1K ﹤0.01% 1495
2025
Q4 		$217K Sell
11,071
-36,609
-77% -$693K ﹤0.01% 1661
2025
Q3 		$603K Buy
47,680
+7,059
+17% +$80.5K ﹤0.01% 1106
2025
Q2 		$387K Sell
40,621
-3,059
-7% -$33.7K ﹤0.01% 1299
2025
Q1 		$457K Buy
43,680
+17,662
+68% +$253K ﹤0.01% 1235
2024
Q4 		$613K Sell
26,018
-5,839
-18% -$173K 0.01% 1168
2024
Q3 		$1.14M Buy
+31,857
New +$1.27M 0.01% 1030

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Guggenheim Capital's DYN Position: Q1 2026 in Review

Guggenheim Capital increased its Dyne Therapeutics (DYN) stake by 11% in Q1 2026, buying an estimated $20.1K and bringing the position to 12,236 shares worth $222K. The position accounts for ﹤0.01% of the portfolio, ranked #1495.

Guggenheim Capital first reported a position in DYN in Q3 2024 and has held it in 7 quarters since. The position peaked at $1.14M in Q3 2024. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Guggenheim Capital held 12,236 shares of Dyne Therapeutics worth $222K as of Q1 2026.
  • Guggenheim Capital bought 1,165 Dyne Therapeutics shares in Q1 2026, an estimated $20.1K.
  • Dyne Therapeutics made up ﹤0.01% of Guggenheim Capital's portfolio in Q1 2026, its #1495 holding.
  • Guggenheim Capital first reported a position in Dyne Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Guggenheim Capital's Dyne Therapeutics position peaked at $1.14M in Q3 2024.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Guggenheim Capital's 13F filing for Q1 2026, filed 15 May 2026.